VERA Stock Forecast: Vera Therapeutics, Inc. Price Predictions for 2026-2027
The 14 Wall Street analysts covering Vera Therapeutics, Inc. hold a median 12-month price target of $75 — +194.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (82): Analysts have, on balance, been raising their forecasts.
Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VERA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VERA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +194.9% from it.
Of the 20 most recent actions, 6 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Guggenheim | Maintains | Buy | $76 → $66 |
| 6 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $90 → $75 |
| 6 Nov 2026 | Wedbush | Maintains | Neutral | $34 → $29 |
| 12 Oct 2026 | Leerink Partners | Initiates | Market Perform | $34 |
| 8 Sept 2026 | JP Morgan | Maintains | Overweight | $76 → $83 |
| 17 Aug 2026 | Wedbush | Reiterates | Neutral | $34 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $125 → $90 |
| 11 Aug 2026 | Wedbush | Maintains | Neutral | $43 → $34 |
| 8 July 2026 | Guggenheim | Maintains | Buy | $56 → $76 |
| 8 July 2026 | HC Wainwright & Co. | Maintains | Buy | $110 → $125 |
| 8 July 2026 | TD Cowen | Maintains | Buy | $73 → $78 |
| 8 July 2026 | Wedbush | Maintains | Neutral | $35 → $43 |
| 7 July 2026 | B of A Securities | Maintains | Buy | $65 → $70 |
| 15 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 11 Mar 2026 | Wolfe Research | Upgrade | Outperform | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Dec 2025 | B of A Securities | Maintains | Buy | — |
| 19 Dec 2025 | Goldman Sachs | Maintains | Buy | — |
| 19 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 11 Dec 2025 | Wedbush | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VERA.
This page is one stock. Monday covers all of them.
VERA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VERA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Vera Therapeutics, Inc. returned −8.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VERA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 179.0×
- Price / book
- 5.5×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 16% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −113.5%
- Return on assets
- −54.4%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vera Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$401.9M.
Free cash flow in the twelve months to 30 June 2026: −$339.2M.
Vera Therapeutics, Inc. employs 362 people.
Data provided by Twelve Data
VERA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VERA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VERA
What is the VERA stock price forecast for 2026-2027?
The 14 Wall Street analysts covering Vera Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $29 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VERA stock a buy right now?
Of the 14 analysts covering Vera Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vera Therapeutics, Inc. 37 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VERA?
As at 21 Nov 2026, Vera Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (82 of 100).
Will VERA stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts implies +194.9% from the last close, and Ticker Nerd's factor model ranks Vera Therapeutics, Inc. 37 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VERA stock forecast for 2030?
No analyst covering Vera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $100 over the next 12 months.
How has VERA stock performed over the past year?
Vera Therapeutics, Inc. returned -8.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vera Therapeutics, Inc. do?
Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases.
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics operates in the biotechnology and health technology sectors, where its work targets conditions driven by abnormal immune activity and unmet medical needs. Headquartered in Brisbane, California, the company’s business today is centered on advancing immunology-focused drug candidates through clinical development and toward commercialization.
CEO Dr. Marshall W. Fordyce M.D. · 362 employees · United States · https://veratx.com